Acalabrutinib

What is Acalabrutinib?

Acalabrutinib  is an oral Bruton's tyrosine kinase (BTK) inhibitor used to treat certain types of blood cancers. It works by blocking the BTK enzyme, which is involved in the survival and proliferation of B cells, a type of white blood cell. By inhibiting BTK, acalabrutinib helps to prevent cancerous B cells from growing and dividing. It is primarily used in the treatment of:

• Chronic lymphocytic leukemia (CLL)
• Small lymphocytic lymphoma (SLL)
• Mantle cell lymphoma (MCL) in patients who have received at least one prior treatment.

How to Use Acalabrutinib?

• Administration: Acalabrutinib is taken orally, typically twice daily, with or without food. Swallow the capsule whole with water; do not chew, crush, or open it.
• Dosage: The usual recommended dose is 100 mg taken every 12 hours. However, dosing may vary based on individual factors such as concurrent medications, kidney function, and treatment response.
• Compliance: Follow the prescribed schedule carefully. If you miss a dose and it is more than 3 hours until your next dose, take the missed dose. Otherwise, skip it and continue with your regular dosing schedule. Do not double doses.

What are the Side Effects?

Common side effects include:

• Headache (most common).
• Fatigue.
• Diarrhea.
• Muscle and joint pain.
• Upper respiratory tract infections.
• Bruising.

Serious side effects may include:

• Bleeding (hemorrhage): Increased risk of bleeding can occur, especially if used with blood-thinning medications.
• Infections: Since acalabrutinib affects B cells, it may lower your body’s immune response, leading to an increased risk of infections.
• Heart problems: Atrial fibrillation (irregular heartbeat) has been reported, so monitor for symptoms like dizziness or chest discomfort.
• Second primary cancers: There is a small risk of developing new cancers, including skin cancers, so regular skin checks are recommended.

What are the Precautions?

• Pregnancy and breastfeeding: Acalabrutinib can harm an unborn baby. Women of childbearing age should use effective contraception during treatment and for at least 1 week after the last dose. Breastfeeding is not recommended during treatment.
• Bleeding risk: Because of the potential for serious bleeding, patients taking anticoagulants (blood thinners) or antiplatelet drugs should exercise caution and inform their doctor.
• Infection risk: Acalabrutinib can suppress the immune system. Report any signs of infection (e.g., fever, chills) immediately.
• Drug interactions: Some medications can interfere with acalabrutinib’s effectiveness, such as proton pump inhibitors (PPIs). Inform your healthcare provider about all medications you're taking.

How to Store Acalabrutinib?

• Storage: Store acalabrutinib at room temperature, between 20°C to 25°C (68°F to 77°F), away from moisture, heat, and light. Keep it in its original container and out of reach of children.

Acalabrutinib is a targeted therapy offering an effective treatment for certain B-cell malignancies, such as CLL and MCL. While it provides benefits in controlling cancer progression, it can also carry risks like bleeding and infection. Therefore, patients need to adhere strictly to dosing guidelines and remain vigilant for side effects. Close communication with a healthcare provider is essential for safe and effective use.